Biolight 2025: How Long Does the Parent Cash Box Really Last, and When Does Dilution Return?
Biolight's cash box at the end of 2025 genuinely looked different after the raise, but the real question is what exactly you are measuring: at the parent level this is a NIS 20.5 million cushion and a stated runway of at least 24 months, while at the group level, and without help from the public warrants, dilution risk was pushed out rather than removed.
The main article already argued that the September 2025 raise bought Biolight time, but did not build a revenue engine. This follow-up isolates the question that was compressed there: how long does the parent cash box really last, and when does dilution move back to the center of the story.
The short answer is that two true stories are sitting on top of each other. The comfortable one is that at the end of 2025 the parent held NIS 20.539 million of cash, short-term deposits, and marketable securities, and management wrote that those balances were enough for at least 24 months after 31 December 2025. The less comfortable one is that the company still says it has no activities generating revenue and positive operating cash flows, while the group posted negative operating cash flow of NIS 10.854 million even in the year of the raise.
Three points determine the right read:
- The cash box is real. This is not a parent company leaning only on theoretical optionality. At the solo level, the liquid-asset base is meaningful.
- The cash box looks too small if you stare only at the cash line. At the end of 2025 the group had only NIS 3.978 million of cash and cash equivalents, but also NIS 23.654 million of cash, short-term deposits, and marketable securities.
- Dilution did not disappear, it was deferred. Series 9 was already out of the picture by March 2026, while Series 10 still looked far away from the share price in April 2026.
The cash box only looks small if you read the wrong line
The number that can look alarming on a first pass is NIS 3.978 million, the group's year-end cash and cash equivalents. That is an incomplete read. At the same date the group had NIS 23.654 million of cash, short-term deposits, and marketable securities, of which NIS 20.539 million sat at the parent level.
That matters because the 2025 investing line can look, at first glance, like a brutal NIS 16.174 million cash burn. In practice, the cash-flow statement shows that NIS 14.589 million of that line came from purchases of marketable securities. In other words, most of the negative investing cash flow was liquidity parking after the raise, not cash consumption that permanently left the system.
This chart sharpens the real debate. If you read only the cash line, the box looks almost empty. If you read only the liquid-asset line, the problem looks solved. Both readings are partial. Biolight raised real money in 2025, kept a large portion of it in liquid instruments, but still did not turn the group into a cash-generating business.
Which cash lens matters
To answer the runway question, you first need to choose which cash lens you are using. Two different lenses are legitimate here, and each one answers a different question.
| Reading frame | Liquidity base | Cash-use base | Implied runway | What it says |
|---|---|---|---|---|
| Narrow parent-only reading | NIS 20.539 million at the parent | About NIS 3.5 million, Biolight solo cash use in 2025 excluding investments in held companies and the public equity raise | About 5.9 years | This is the reading that explains why management is comfortable talking about at least 24 months |
| Group operating reading | NIS 23.654 million at the group | NIS 10.854 million of negative operating cash flow | About 2.2 years | This is the reading that reminds you the portfolio still consumes cash even after the raise |
| Management's stated position | Parent balances plus a 24-month forecast budget | Not fully disclosed publicly | At least 24 months | This is a statement about meeting obligations, not proof that dilution is off the table |
What matters is not which row is "correct," but which question it answers. If the question is whether the parent can fund its corporate layer and near-term obligations, the solo reading is reassuring. If the question is whether the group as a whole has already moved beyond funding pressure, that reading is too soft.
That is the gap between time and resolution. The NIS 3.5 million solo use figure is narrow because it excludes investments in held companies. But at Biolight those investments are not a side issue. They are part of the economics of the story. The parent box lasts far longer if the portfolio can fund itself, and far less long if the parent remains the main funding address for the next step.
The public warrants no longer look like a solution
The September 2025 public package included 4,358,100 shares, 4,358,100 Series 9 warrants, and 4,358,100 Series 10 warrants. On paper, that is a very large layer of future capital. On simple arithmetic, a full exercise of Series 10 alone could have brought in about NIS 32.7 million gross and added roughly 48% to the year-end 2025 issued share count. If both series had been fully exercised, the gross potential was about NIS 58.8 million.
But this is exactly where the difference between paper optionality and practical financing shows up. Series 9 carried an exercise price of NIS 6 with a final exercise date of 21 March 2026. Series 10 carried an exercise price of NIS 7.5 with a final exercise date of 21 March 2027. On 6 April 2026 the ordinary share traded at 270 agorot, and only Series 10 still appeared in the tradable securities list.
| Instrument | Final exercise date | Strike price | Practical read in April 2026 |
|---|---|---|---|
| Series 9 | 21 March 2026 | NIS 6 | The exercise window had already closed |
| Series 10 | 21 March 2027 | NIS 7.5 | Still traded, but still far out of the money |
That is why the warrants no longer look like a backstop you can rely on comfortably. They remained mainly a reminder that future dilution could be large if the share price rises dramatically, but as of April 2026 they did not look like a near-term funding source. That matters even more because Biolight still does not rest on revenue and positive cash generation. When the share price sits far below the strike, the warrants stop functioning as a financing bridge and remain mostly a reminder of potential dilution.
When dilution returns to the center
Dilution does not return to the center on the day the cash box reaches zero. It returns earlier, at the point when the market starts to think the next milestone is farther away than the remaining cushion. That is the real test at Biolight.
Management can reasonably stand behind the 24-month statement, and the solo numbers give it support. But once the Series 9 window has closed, and Series 10 remains far below its strike relative to the share price, the market can no longer assume that the 2025 public package will fund the next step by itself. That means the next step has to come from the portfolio: outside funding at one of the companies, commercialization, licensing, or a regulatory event that opens up new value.
On a conservative reading, if the 2025 pace of negative operating cash flow remains similar, and the held layers continue to need cash, the conversation about new capital will begin well before the end of the 24-month window. On the other hand, if one of the portfolio companies raises money at its own level, or if a commercial step reduces reliance on the parent, the solo cash box can absolutely last for a meaningful period without a new dilution event.
So the right question for 2026 and 2027 is not "how much cash is there today," but "who is supposed to fund the next milestone." As long as the answer remains the parent company, dilution stays in the picture. The moment the answer shifts to one of the assets, an outside funder, a strategic partner, or a public market at the portfolio-company level, the runway starts to look very different.
Conclusion
Biolight's parent cash box at the end of 2025 is real, liquid, and large enough to support the 24-month statement. But it is still not a cash box that removes dilution from the equation. It only pushes the issue out and gives the company a window to prove that the portfolio can create financing, commercialization, or accessible value before that window narrows.
In that sense, 2026 will not be judged only by the cash balance. It will be judged by whether Biolight can move the center of gravity from the word "cash box" to the word "proof." If it can, the 2025 raise will look, in hindsight, like financing that bought time to exploit an opportunity. If it cannot, the same cash box will look more like another stop on the way to a new capital round.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.